Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.

Erkut N, Menteşe A, Özbaş HM, Ermantaş N, Sümer A, Örem A, Sönmez M.

Turk J Haematol. 2016 Jun 5;33(2):135-40. doi: 10.4274/tjh.2014.0405. Epub 2015 Aug 6.

2.

VEGF-initiated angiogenesis and the uPA/uPAR system.

Breuss JM, Uhrin P.

Cell Adh Migr. 2012 Nov-Dec;6(6):535-615. doi: 10.4161/cam.22243. Epub 2012 Oct 17. Review.

3.

BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.

Morodomi Y, Yano T, Kinoh H, Harada Y, Saito S, Kyuragi R, Yoshida K, Onimaru M, Shoji F, Yoshida T, Ito K, Shikada Y, Maruyama R, Hasegawa M, Maehara Y, Yonemitsu Y.

Mol Ther. 2012 Apr;20(4):769-77. doi: 10.1038/mt.2011.305. Epub 2012 Feb 7.

4.

Challenges for drug discovery - a case study of urokinase receptor inhibition.

Chen Z, Lin L, Huai Q, Huang M.

Comb Chem High Throughput Screen. 2009 Dec;12(10):961-7.

5.

Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy.

Basu A, Menicucci G, Maestas J, Das A, McGuire P.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4974-81. doi: 10.1167/iovs.09-3619. Epub 2009 May 14.

6.
7.

Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.

Wang H, Hicks J, Khanbolooki P, Kim SJ, Yan C, Wang Y, Boyd D.

Am J Pathol. 2003 Aug;163(2):453-64.

8.
11.

Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.

Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F.

EMBO J. 1996 Apr 1;15(7):1572-82.

12.
13.

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Jänicke F, et al.

J Clin Invest. 1993 Nov;92(5):2160-7.

14.
16.

Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.

Cubellis MV, Andreasen P, Ragno P, Mayer M, Danø K, Blasi F.

Proc Natl Acad Sci U S A. 1989 Jul;86(13):4828-32.

17.

Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.

Picone R, Kajtaniak EL, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Danø K, Blasi F.

J Cell Biol. 1989 Feb;108(2):693-702.

18.

Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.

Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A.

J Cell Biol. 1989 May;108(5):1987-95.

19.

Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix.

Grøndahl-Hansen J, Kirkeby LT, Ralfkiaer E, Kristensen P, Lund LR, Danø K.

Am J Pathol. 1989 Oct;135(4):631-6.

Supplemental Content

Support Center